Healthcare
Syndax Pharmaceuticals, Inc.(SNDX)
Live Price
Offline$18.39
-2.44% today
1Y Change
+113.17%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $1.69B
- Revenue Growth
- +627.8%
- EPS Growth
- +11.8%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syndax Pharmaceuticals, Inc. (SNDX) is a Healthcare stock with a market cap of $1.69B and listed on NASDAQ. The stock last traded around $18.39 and up 113.2% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +627.8%, EPS growth of +11.8%, a dividend yield of 0.0%. What stands out right now is revenue +627.8%, EPS +11.8%, free cash flow -17.6% with operating margin -102.9% and ROIC -57.8%. Valuation sits in the middle of the pack at price/sales 7.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SNDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+627.8% vs +7.6% peer median
Operating Margin
Below sector median
-102.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +627.8% and EPS at +11.8%, with operating margin around -102.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +0.7% | +7.1% | โ |
2026 Feb 26, 2026 | -33.5% | +5.0% | +4.4% | +19.5% |
2025 Nov 3, 2025 | +5.4% | +11.6% | +14.2% | +36.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNDX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNDX Max Drawdown
-24.02%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNDX and SPY.
Company Overview
Syndax Pharmaceuticals, Inc.
NASDAQ Global Select
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
- Leadership
- Michael A. Metzger
- IPO Date
- Mar 2, 2016
- Employees
- 270
- Street Address
- 35 Gatehouse Drive
- Mailing
- New York City, MA, 02451
- Region
- New York City, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 419 1400
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.8
- Price/Book
- 39.8
Growth
- Revenue
- +627.8%
- EPS
- +11.8%
- Free Cash Flow
- -17.6%
Profitability
- Gross Margin
- 98.0%
- Operating Margin
- -102.9%
- Net Margin
- -112.0%
- ROE
- -256.7%
- ROIC
- -57.8%
Balance Sheet
- Debt/Equity
- 8.30
- Current Ratio
- 5.47
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.